Publications by authors named "L Philipps"
Background And Objective: Delivering radiotherapy to the bladder is challenging as it is a mobile, deformable structure. Dose-escalated adaptive image-guided radiotherapy could improve outcomes. RAIDER aimed to demonstrate the safety of such a schedule.
View Article and Find Full Text PDFIntroduction: Patient-reported outcomes (PRO) are currently collected from trial participants using paper questionnaires by the Clinical Trials and Statistics Unit at The Institute of Cancer Research (ICR-CTSU). Streamlining PRO collection using electronic questionnaires (ePRO) may improve data collection and patient experience. Here, we outline our protocol for a Study within a trial of electronic versus paper-based Patient-Reported oUtcomes CollEction (SPRUCE), which investigates the acceptability of ePRO in oncology clinical trials.
View Article and Find Full Text PDFArticle Synopsis
- Adding concurrent chemotherapy to radiotherapy enhances treatment outcomes for patients with muscle-invasive bladder cancer, with a meta-analysis indicating better disease control with a hypofractionated schedule.
- The RAIDER clinical trial compared standard and adaptive radiotherapy in patients with unifocal bladder cancer, assessing acute toxicity based on therapy and fractionation schedules.
- Results showed that individuals receiving concomitant therapy experienced significantly higher rates of acute grade 2+ gastrointestinal toxicity in the 20-fraction group, but not in the 32-fraction group, highlighting differences in toxicity based on treatment regimens.
Correlation of Clinician- and Patient-Reported Outcomes in the BC2001 Trial.
Clin Oncol (R Coll Radiol)
May 2023
Aims: To evaluate whether there is sufficient correlation between patient-reported outcomes (PROs) and clinician-reported outcomes (CROs) in bladder cancer follow-up post-radiotherapy to streamline data collection and to reduce trial follow-up burden on patients, clinicians and trial programmes.
Materials And Methods: PROs data were collected within the BC2001 trial using the Functional Assessment of Cancer Therapy specific to bladder cancer (FACT-BL) questionnaire. CROs data were collected by clinicians using Late Effects in Normal Tissues Subjective, Objective and Management (LENT/SOM).
Aims: BC2001, a randomised trial of treatment for muscle-invasive bladder cancer, demonstrated no difference in health-related quality of life (HRQoL) or late toxicity between patients receiving radical radiotherapy with and without chemotherapy. This secondary analysis explored sex-based differences in HRQoL and toxicity.
Materials And Methods: Participants completed the Functional Assessment of Cancer Therapy Bladder (FACT-BL) HRQoL questionnaires at baseline, end of treatment, 6 months and annually until 5 years.